Exsulin reports diabetes data

Exsulin Corp. (Minneapolis, Minn.) reported mixed results from a pair of double-blind Phase II trials of Exsulin to treat diabetes. In the SPIRIT 1 trial to treat Type I diabetes in 63 patients, once-daily injections of 600 mg Exsulin met the co-primary endpoint of significantly increasing arginine-stimulated C-peptide from baseline vs. placebo at day 56 but missed the co-primary endpoint of reducing HbA1c vs. placebo. ...